Quarter‑over‑quarter performance
Synergy CHC Corp. disclosed that net income for the quarter ended 30 June 2025 was $42.3 million, up from $31.1 million in the same quarter a year earlier – a 36 % year‑over‑year increase. Diluted earnings per share (EPS) rose to $0.84 versus $0.62 in Q2 2024, representing a 35 % jump and the company’s tenth straight quarter of profitability.
Trading implications
The strong YoY lift in both net income and EPS underscores the durability of Synergy’s consumer‑health franchise and its ability to translate top‑line growth into bottom‑line expansion. The earnings beat has already nudged the stock higher on the news flow, but the price still trades below its 52‑week high, leaving room for a short‑term pull‑back rally on the breakout. From a technical standpoint, the shares are holding above the 20‑day SMA (~$18.70) and have found support near the 61.8% Fibonacci retracement of the recent uptrend (≈$19.10). A buy‑on‑dip around $19.00–$19.30, with a target near the prior swing high of $21.20 and a stop just below $18.70, aligns the fundamentals‑driven upside with a disciplined risk profile. Conversely, if the market digests the results and the price stalls below $18.70, a re‑evaluation of the upside may be warranted, as the momentum could be weakening despite the solid earnings backdrop.